• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.左旋多巴联合脑外多巴脱羧酶抑制剂L-α-甲基多巴肼治疗帕金森病。
J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10-4. doi: 10.1136/jnnp.36.1.10.
2
Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.左旋多巴与MK 486（L-α-甲基多巴肼）联合应用——一种帕金森病外周脱羧酶抑制剂。
Med J Aust. 1974 Mar 23;1(12):429-32.
3
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.用脑外脱羧酶抑制剂与左旋多巴联合治疗特发性帕金森病。
Br Med J. 1971 Sep 25;3(5777):729-32. doi: 10.1136/bmj.3.5777.729.
4
Alpha methyldopahydrazine as an adjunct to levodopa therapy in Parkinson's disease.α-甲基多巴肼作为左旋多巴治疗帕金森病的辅助药物。
Can J Neurol Sci. 1975 Aug;2(3):169-72. doi: 10.1017/s0317167100020205.
5
Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
Neurology. 1974 Mar;24(3):263-5. doi: 10.1212/wnl.24.3.263.
6
Ro 4-4602 and levodopa in the treatment of Parkinsonism.
Neurology. 1974 May;24(5):482-6. doi: 10.1212/wnl.24.5.482.
7
Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.两种脑外多巴脱羧酶抑制剂在帕金森病中的疗效比较
Neurology. 1978 Sep;28(9 Pt 1):964-8. doi: 10.1212/wnl.28.9.964.
8
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone.左旋多巴联合卡比多巴治疗帕金森病患者与单用左旋多巴治疗的一年对比。
Lancet. 1973 Dec 29;2(7844):1459-62. doi: 10.1016/s0140-6736(73)92729-3.
9
Carbidopa in Parkinson disease and in nausea and vomiting of levodopa.卡比多巴用于帕金森病及左旋多巴引起的恶心和呕吐。
Arch Neurol. 1974 Aug;31(2):128-33. doi: 10.1001/archneur.1974.00490380076010.
10
Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
Arch Neurol. 1975 Aug;32(8):560-3. doi: 10.1001/archneur.1975.00490500080010.

引用本文的文献

1
Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery.脑屏障转运体的药物蛋白质组学与脑靶向药物递送的底物设计
Pharm Res. 2022 Jul;39(7):1363-1392. doi: 10.1007/s11095-022-03193-2. Epub 2022 Mar 7.
2
Levodopa-Responsive Chorea: A Review.左旋多巴反应性舞蹈症：综述
Ann Indian Acad Neurol. 2020 Mar-Apr;23(2):211-214. doi: 10.4103/aian.AIAN_221_19. Epub 2020 Feb 25.
3
Effects of magnesium oxide on pharmacokinetics of L-dopa/carbidopa and assessment of pharmacodynamic changes by a model-based simulation.氧化镁对左旋多巴/卡比多巴药代动力学的影响及基于模型模拟的药效学变化评估。
Eur J Clin Pharmacol. 2019 Mar;75(3):351-361. doi: 10.1007/s00228-018-2568-4. Epub 2018 Oct 31.
4
in Parkinson disease: A double-blind, randomized, controlled, crossover study.帕金森病：一项双盲、随机、对照、交叉研究。
Neurology. 2017 Aug 1;89(5):432-438. doi: 10.1212/WNL.0000000000004175. Epub 2017 Jul 5.
5
Plasma dopa concentrations after different preparations of levodopa in normal subjects.正常受试者中不同左旋多巴制剂给药后的血浆多巴浓度。
Br J Clin Pharmacol. 1976 Dec;3(6):983-90. doi: 10.1111/j.1365-2125.1976.tb00347.x.
6
Bromocriptine and dopamine receptor stimulation.溴隐亭和多巴胺受体刺激。
Br J Clin Pharmacol. 1976 Dec;3(6):977-82. doi: 10.1111/j.1365-2125.1976.tb00346.x.
7
Does levodopa accelerate Parkinson's disease?左旋多巴会加速帕金森病的发展吗？
Drugs Aging. 1999 Jun;14(6):399-408. doi: 10.2165/00002512-199914060-00001.
8
Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson's disease.苯海索、金刚烷胺和左旋多巴治疗帕金森病的对比试验。
J Neurol Neurosurg Psychiatry. 1974 Apr;37(4):422-6. doi: 10.1136/jnnp.37.4.422.
9
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].帕金森病的鉴别治疗，特别提及医源性疾病的可能性（作者译）
Arch Psychiatr Nervenkr (1970). 1974 Apr 9;218(4):319-38. doi: 10.1007/BF00342576.
10
Anticholinergic withdrawal and benzhexol treatment in Parkinson's disease.帕金森病中的抗胆碱能戒断与苯海索治疗
J Neurol Neurosurg Psychiatry. 1973 Dec;36(6):936-41. doi: 10.1136/jnnp.36.6.936.

本文引用的文献

1
Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA.α-甲基多巴的肼基类似物对多巴脱羧酶的抑制作用。
Biochem Pharmacol. 1962 Nov;11:1067-77. doi: 10.1016/0006-2952(62)90166-1.
2
Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase.外周脱羧酶抑制后，3,4-二羟基苯丙氨酸引起脑内儿茶酚胺增加。
Nature. 1967 Aug 19;215(5103):852-3. doi: 10.1038/215852b0.
3
Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis.对去甲肾上腺素生物合成过程中涉及的三种酶的抑制剂在体内产生的生化效应的评估。
Mol Pharmacol. 1966 Mar;2(2):95-105.
4
[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].口服左旋多巴联合脱羧酶抑制剂（Ro IV 46.02）治疗帕金森综合征
Presse Med (1893). 1969 Apr 5;77(17):619-22.
5
Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.左旋多巴单独及与脑外脱羧酶抑制剂联合应用对血压及某些心血管反射的影响。
Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740-6. doi: 10.1002/cpt1970115740.
6
[Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].
Wien Klin Wochenschr. 1969 Sep 26;81(39):677-9.
7
Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).α-甲基多巴肼（MK-486）对帕金森病左旋多巴治疗的改良作用
Trans Am Neurol Assoc. 1971;96:55-8.
8
Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa.用脑外脱羧酶抑制剂与左旋多巴联合治疗特发性帕金森病。
Br Med J. 1971 Sep 25;3(5777):729-32. doi: 10.1136/bmj.3.5777.729.
9
Treatment of Parkinson's disease with levodopa and Ro 4-4602.左旋多巴和Ro 4-4602治疗帕金森病
Clin Pharmacol Ther. 1971 Mar-Apr;12(2):353-9. doi: 10.1002/cpt1971122part2353.
10
Modification of Parkinsonism--chronic treatment with L-dopa.帕金森病的改善——左旋多巴的长期治疗
N Engl J Med. 1969 Feb 13;280(7):337-45. doi: 10.1056/NEJM196902132800701.

左旋多巴联合脑外多巴脱羧酶抑制剂L-α-甲基多巴肼治疗帕金森病。

Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

作者信息

Marsden C D, Barry P E, Parkes J D, Zilkha K J

出版信息

J Neurol Neurosurg Psychiatry. 1973 Feb;36(1):10-4. doi: 10.1136/jnnp.36.1.10.

DOI:10.1136/jnnp.36.1.10
PMID:4691682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC494269/
Abstract

Thirty patients with Parkinson's disease were treated for four weeks with levodopa combined with an inhibitor of extracerebral dopa decarboxylase, L-alpha-methyldopahydrazine (MK 486). The therapeutic results were compared with the effects of treatment of a group of 40 patients with levodopa alone. Patients treated with the combined therapy improved more rapidly, had less nausea and vomiting, and required a much smaller dose of levodopa than patients treated with levodopa by itself.

摘要

30名帕金森病患者接受了左旋多巴与脑外多巴脱羧酶抑制剂L-α-甲基多巴肼（MK 486）联合治疗四周。将治疗结果与40名单独使用左旋多巴治疗的患者的疗效进行了比较。联合治疗的患者改善更快，恶心和呕吐更少，并且与单独使用左旋多巴治疗的患者相比，所需的左旋多巴剂量要小得多。